Refine by
Cancer Nsclc Suppliers & Manufacturers
27 companies found
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several ...
based inSyracuse, NEW YORK (USA)
Mesothelioma is an aggressive cancer that affects the lining of the lungs, heart, or abdomen. Caused by the inhalation of asbestos fibers, mesothelioma is often diagnosed in older individuals who worked with asbestos products. Prognosis for ...
Lung cancer is one of the most common cancers, and researchers estimate about 3 – 4% of all cases can be attributed to asbestos ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian ...
based inVienna, AUSTRIA
ViennaLab Diagnostics specializes in easy-to-use in vitro diagnostic assays for the detection of genetic variants associated with genetic disorders, genetic predispositions, pharmacogenetics, cancer, and the human microbiome. Our focus is on product ...
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during ...
based inWoodcliff Lake, NEW JERSEY (USA)
Eagle is a specialty pharmaceutical company working to advance safe and efficient injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, we are committed to developing innovative drugs that result in ...
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
Harnessing the Anticancer Power of Hydrogen Peroxide: As cancer cells are more susceptible than normal cells to increased levels of hydrogen peroxide, we believe the conversion of radiation-generated superoxide to hydrogen peroxide by our selective ...
based inBarcelona, SPAIN
INTERmedic is a dynamic company that is still expanding, after more than 25 years in the medical technology business sector. INTERmedic develops, manufactures and distributes innovative medical systems, based on the most advanced laser technology ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
PathExploreTM offers unprecedented spatial and cellular resolution of the tumor microenvironment (TME) from H&E images. PathExplore is an AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
based inTokyo, JAPAN
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich ...
ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inWashington, DISTRICT OF COLUMBIA (USA)
TriStar is a Maryland LLC founded in 2003 with a business office in Washington DC. Our manufacturing, IHC and Molecular Lab is in Catania (Italy) and collaborating Medical institutes in Germany, Italy, UK & France TriStar has pioneered the use of ...
Molecular Data: Yes; Approx. # of Donors: 72; Follow Up Data: No; Cores per Donor: 2; Core Size: 1mm; Approx. # of Cores *: 144; TA number: TA3124; List of markers: CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, PD1, PD-L1(22C3); Suitable for (IHC or ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including ...
based inSarıyer, TURKEY
Virasoft Inc. was founded in 2015 with the support of the Turkish Ministry of Industry and Technology. We develop institution-specific projects in 4 main areas that meet all the needs of an institution in digital pathology. We focus on four main ...
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...